HSV 2 Formulation 5

**HSV 2 Formulation 5** is an opaque intervention label used for one intramuscular investigational therapeutic vaccine formulation in Sanofi's HSV15 study in adults with recurrent genital herpes caused by herpes simplex virus type 2. Publicly available study materials identify multiple vaccine candidates and regimens evaluated in the program, including G103, modified G103, HSV-529, GLA-SE-adjuvanted HSV-529, and a G103 plus HSV-529 regimen, but do not publicly map the specific label \"HSV 2 Formulation 5\" to one of those underlying products. The HSV15 trial was terminated after its Phase 1 portion when Sanofi stopped the HSV0148 project; the planned Phase 2 efficacy portion was not conducted. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04222985))